JP7317505B2 - 腫瘍死滅に影響する二重標的構築物 - Google Patents

腫瘍死滅に影響する二重標的構築物 Download PDF

Info

Publication number
JP7317505B2
JP7317505B2 JP2018567684A JP2018567684A JP7317505B2 JP 7317505 B2 JP7317505 B2 JP 7317505B2 JP 2018567684 A JP2018567684 A JP 2018567684A JP 2018567684 A JP2018567684 A JP 2018567684A JP 7317505 B2 JP7317505 B2 JP 7317505B2
Authority
JP
Japan
Prior art keywords
cancer
groups
substituted
compound
rps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018567684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528243A (ja
Inventor
ダブリュ. バビック,ジョン
エム. ケリー,ジェームズ
アモル-コアラサ,アレハンドロ
ポンナラ,シャシカンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of JP2019528243A publication Critical patent/JP2019528243A/ja
Priority to JP2023060583A priority Critical patent/JP2023103205A/ja
Application granted granted Critical
Publication of JP7317505B2 publication Critical patent/JP7317505B2/ja
Priority to JP2025116381A priority patent/JP2025148450A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018567684A 2016-06-23 2017-06-22 腫瘍死滅に影響する二重標的構築物 Active JP7317505B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023060583A JP2023103205A (ja) 2016-06-23 2023-04-04 腫瘍死滅に影響する二重標的構築物
JP2025116381A JP2025148450A (ja) 2016-06-23 2025-07-10 腫瘍死滅に影響する二重標的構築物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353735P 2016-06-23 2016-06-23
US62/353,735 2016-06-23
PCT/US2017/038832 WO2017223357A1 (en) 2016-06-23 2017-06-22 Double targeted constructs to affect tumor kill

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023060583A Division JP2023103205A (ja) 2016-06-23 2023-04-04 腫瘍死滅に影響する二重標的構築物

Publications (2)

Publication Number Publication Date
JP2019528243A JP2019528243A (ja) 2019-10-10
JP7317505B2 true JP7317505B2 (ja) 2023-07-31

Family

ID=60675799

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018567684A Active JP7317505B2 (ja) 2016-06-23 2017-06-22 腫瘍死滅に影響する二重標的構築物
JP2023060583A Pending JP2023103205A (ja) 2016-06-23 2023-04-04 腫瘍死滅に影響する二重標的構築物
JP2025116381A Pending JP2025148450A (ja) 2016-06-23 2025-07-10 腫瘍死滅に影響する二重標的構築物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023060583A Pending JP2023103205A (ja) 2016-06-23 2023-04-04 腫瘍死滅に影響する二重標的構築物
JP2025116381A Pending JP2025148450A (ja) 2016-06-23 2025-07-10 腫瘍死滅に影響する二重標的構築物

Country Status (10)

Country Link
US (4) US10179117B2 (cg-RX-API-DMAC7.html)
EP (2) EP3474903B1 (cg-RX-API-DMAC7.html)
JP (3) JP7317505B2 (cg-RX-API-DMAC7.html)
KR (2) KR102864909B1 (cg-RX-API-DMAC7.html)
CN (2) CN109843339B (cg-RX-API-DMAC7.html)
AU (2) AU2017281364B2 (cg-RX-API-DMAC7.html)
CA (1) CA3028978A1 (cg-RX-API-DMAC7.html)
IL (1) IL263863B (cg-RX-API-DMAC7.html)
SG (1) SG11201811482YA (cg-RX-API-DMAC7.html)
WO (1) WO2017223357A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
SG11201811482YA (en) * 2016-06-23 2019-01-30 Univ Cornell Double targeted constructs to affect tumor kill
MX392700B (es) 2016-08-10 2025-03-11 Cancer Targeted Tech Llc Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados.
CN109982998A (zh) * 2016-11-23 2019-07-05 癌靶技术有限责任公司 白蛋白结合psma抑制剂
JP7373998B2 (ja) 2017-05-02 2023-11-06 コーネル・ユニバーシティー 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
KR102403970B1 (ko) * 2018-12-27 2022-05-31 (주)퓨쳐켐 카르복시산이 도입된 psma-표적 화합물 및 그의 용도
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
KR20230173150A (ko) 2021-04-20 2023-12-26 테라파워, 엘엘씨 Ac-225 생성용 티타니아 기반 발생기
CN115448856B (zh) * 2022-09-30 2023-09-22 北京师范大学 一种用于靶向PSMA的EuK二聚体化合物、衍生物及其应用
WO2025213026A1 (en) * 2024-04-04 2025-10-09 Lantheus Medical Imaging, Inc. Astatine-211-labelled psma-binding compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008053360A2 (en) 2006-11-03 2008-05-08 Philochem Ag Albumin binding molecules and uses thereof
JP2010509358A (ja) 2006-11-08 2010-03-25 バイオストリーム セラピューティクス インコーポレーティッド グルタミン酸のヘテロダイマー
JP2011529919A (ja) 2008-08-01 2011-12-15 ザ ジョンズ ホプキンズ ユニヴァーシティー Psma結合剤及びその使用
JP2012511023A (ja) 2008-12-05 2012-05-17 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド テクネチウム−及びレニウム−ビス(ヘテロアリール)錯体及びpsmaを阻害するその使用方法
WO2017070482A2 (en) 2015-10-22 2017-04-27 The Johns Hopkins University Psma targeted radiohalogenated ureas for cancer radiotherapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
WO2006091796A2 (en) 2005-02-22 2006-08-31 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
WO2010032248A2 (en) 2008-09-17 2010-03-25 Yeda Research And Development Co. Ltd. Multifunctional albumin conjugates
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
JP5843338B2 (ja) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
DK2766364T3 (da) 2011-08-17 2024-09-30 Merck & Cie Folatkonjugater af albumin-bindende enheder
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10140408B2 (en) 2015-09-04 2018-11-27 Qualcomm Incorporated Selectively encrypting content for distribution from a receiver device to a companion device
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
SG11201811482YA (en) * 2016-06-23 2019-01-30 Univ Cornell Double targeted constructs to affect tumor kill
KR102724812B1 (ko) 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
US11400165B2 (en) 2017-11-04 2022-08-02 Advanced Proteome Therapeutics Inc. Composition and method for modifying polypeptides
KR20210148157A (ko) 2019-04-03 2021-12-07 타베다 세라퓨틱스, 인코포레이티드 Hsp90-결합 접합체 및 이의 제형
ES3075769T3 (en) 2019-05-10 2026-08-07 Janssen Biotech Inc Macrocyclic chelators and methods of use thereof
US12151004B2 (en) 2020-01-31 2024-11-26 University Of Saskatchewan Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies
CA3070610A1 (en) 2020-01-31 2021-07-31 Humphrey FONGE Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies
US20220143228A1 (en) 2020-10-22 2022-05-12 Actinium Pharmaceuticals, Inc. Her3 radioimmunotherapy for the treatment of solid cancers
TW202233244A (zh) 2020-11-10 2022-09-01 美商健生生物科技公司 巨環化合物及其使用方法
AU2022213825A1 (en) 2021-01-27 2023-09-14 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
GEAP202316335A (en) 2021-02-01 2023-10-10 Bayer Ag Multimeric chelator compounds for use in targeted radiotherapy
MX2023014069A (es) 2021-05-27 2024-03-15 Janssen Biotech Inc Composiciones y métodos para el tratamiento del cáncer de próstata.
WO2023026236A1 (en) 2021-08-27 2023-03-02 Janssen Biotech, Inc. Anti-psma radioconjugates and uses thereof
WO2023026235A1 (en) 2021-08-27 2023-03-02 Janssen Biotech, Inc. Anti-psma antibodies and uses thereof
EP4408839A4 (en) 2021-09-29 2025-08-06 Univ Melbourne MACROCYCLE-CONTAINING COMPOUNDS AND THEIR RADIOLABELED COMPLEXES, USED AS LIGANDS IN TARGETED RADIOTHERAPY APPLICATIONS
WO2023084396A1 (en) 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and methods of making the same
EP4429718A1 (en) 2021-11-09 2024-09-18 Janssen Biotech, Inc. Macrocyclic compounds and diagnostic uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008053360A2 (en) 2006-11-03 2008-05-08 Philochem Ag Albumin binding molecules and uses thereof
JP2010509358A (ja) 2006-11-08 2010-03-25 バイオストリーム セラピューティクス インコーポレーティッド グルタミン酸のヘテロダイマー
JP2011529919A (ja) 2008-08-01 2011-12-15 ザ ジョンズ ホプキンズ ユニヴァーシティー Psma結合剤及びその使用
JP2012511023A (ja) 2008-12-05 2012-05-17 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド テクネチウム−及びレニウム−ビス(ヘテロアリール)錯体及びpsmaを阻害するその使用方法
WO2017070482A2 (en) 2015-10-22 2017-04-27 The Johns Hopkins University Psma targeted radiohalogenated ureas for cancer radiotherapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HILLIER, S. M. et al.,Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer,Cancer Research,2009年,69(17),pp. 6932-6940
KIESS, A. P. et al.,(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy,Journal of Nuclear Medicine,2016年,57,pp. 1569-1575
KUMAR, A. et al.,Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics,Bioconjugate Chemistry,2016年,27(7),pp. 1681-1689
WANG, H. et al.,Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies,Bioorganic & Medicinal Chemistry Letters,2010年,20(1),pp. 392-397

Also Published As

Publication number Publication date
JP2019528243A (ja) 2019-10-10
KR20190039080A (ko) 2019-04-10
NZ749712A (en) 2025-03-28
AU2017281364A1 (en) 2019-01-24
IL263863A (en) 2019-01-31
EP3474903A1 (en) 2019-05-01
US10716772B2 (en) 2020-07-21
AU2023203581A1 (en) 2023-07-06
AU2017281364B2 (en) 2023-06-22
EP3474903B1 (en) 2025-01-22
CA3028978A1 (en) 2017-12-28
NZ789339A (en) 2025-06-27
AU2023203581B2 (en) 2025-05-22
EP4520745A3 (en) 2025-05-14
US20190142770A1 (en) 2019-05-16
JP2023103205A (ja) 2023-07-26
WO2017223357A1 (en) 2017-12-28
US10179117B2 (en) 2019-01-15
EP4520745A2 (en) 2025-03-12
CN109843339A (zh) 2019-06-04
US12186288B2 (en) 2025-01-07
US20210137860A1 (en) 2021-05-13
KR102864909B1 (ko) 2025-09-25
KR102513698B1 (ko) 2023-03-23
IL263863B (en) 2021-10-31
SG11201811482YA (en) 2019-01-30
JP2025148450A (ja) 2025-10-07
KR20230043239A (ko) 2023-03-30
CN109843339B (zh) 2023-07-07
US20170368005A1 (en) 2017-12-28
EP3474903A4 (en) 2020-02-26
CN117069621A (zh) 2023-11-17
US20260091008A1 (en) 2026-04-02

Similar Documents

Publication Publication Date Title
US20260091008A1 (en) Double targeted constructs to affect tumor kill
KR102724812B1 (ko) 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
JP7622113B2 (ja) Psma阻害剤を含有する18f標識トリアゾール
US12377175B2 (en) Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
HK40007144B (en) Double targeted constructs to affect tumor kill
HK40007144A (en) Double targeted constructs to affect tumor kill
HK40009754B (en) 18f-labeled triazole containing psma inhibitors
HK40009754A (en) 18f-labeled triazole containing psma inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200608

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230404

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230417

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230417

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230719

R150 Certificate of patent or registration of utility model

Ref document number: 7317505

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250